NCT01790932View on ClinicalTrials.gov

BKM120 For Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Breast Cancer
Interventions
DRUG

BKM120

Trial Locations (4)

02130

Dana-Farber Cancer Institute at Faulkner Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01790932 - BKM120 For Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter